The role of tadalafil for lower urinary tract symptoms after brachytherapy

The role of tadalafil for lower urinary tract symptoms after brachytherapy - Tadalafil after brachytherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015767

Enrollment

200

Registered

2014-12-01

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic cancer

Interventions

Tadalafil 5mg, p.o. Tamsulosin 0.2mg, p.o.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients of prostate cancer, who received brachytherapy

Exclusion criteria

Exclusion criteria: 1) Past history of urethral or prostatic surgery 2) Past history of radiation therapy for pelvic organs 3) History of severe neurogenic disorder of lower urinary tract including Parkinson disease, diabetes mellitus, etc..

Design outcomes

Primary

Measure	Time frame
International prostate symptom score Overactive bladder score	—

Secondary

Measure	Time frame
Uroflowmetry (Qmax, Qave,Voided volume), residual urine, IIEF5, blood pressure, heart rate, complication (hematuria, rectal bleeding), blood test (PSA, total protein, albumin, hemoglobin, hematocrit)	—

Countries

Japan

Contacts

Public ContactTomonori Minagawa

Shinshu University Hospital Urology

minagawat@shinshu-u.ac.jp0263372661

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026